Results 21 to 30 of about 453,251 (315)

Covalent Modification of the JH2 Domain of Janus Kinase 2. [PDF]

ACS Med Chem Lett, 2022
Probe molecules that covalently modify the JAK2 pseudokinase domain (JH2) are reported. Selective targeting of JH2 domains over the kinase (JH1) domains is a necessary feature for ligands intended to evaluate JH2 domains as therapeutic targets. The JH2 domains of three Janus kinases (JAK1, JAK2, and TYK2) possess a cysteine residue in the catalytic ...
Henry SP, Liosi ME, Ippolito JA, Menges F, Newton AS, Schlessinger J, Jorgensen WL.   +6 more
europepmc   +3 more sources

Tyrosine Kinase 2 and Janus Kinase‒Signal Transducer and Activator of Transcription Signaling and Inhibition in Plaque Psoriasis.

Journal of American Academy of Dermatology, 2021
Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. The Janus kinase‒signal transducer and activator of transcription (JAK-STAT) pathway plays a major role in intracellular cytokine signaling in inflammatory processes ...
J. Krueger, I. McInnes, A. Blauvelt
semanticscholar   +1 more source

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

Dermatologic Therapy, 2021
Deucravacitinib, a novel, oral, selective inhibitor of tyrosine kinase 2 (TYK2) signaling, acts via an allosteric mechanism by binding to the enzyme’s regulatory domain instead of the catalytic domain.
A. Chimalakonda, J. Burke, Lihong Cheng, I. Catlett, M. Tagen, Qihong Zhao, Aditya Patel, Jun Shen, I. Girgis, Subhashish Banerjee, J. Throup   +10 more
semanticscholar   +1 more source

Itch and Janus Kinase Inhibitors

Acta Dermato-Venereologica, 2023
Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways.
Yujin Han, Yu Ri Woo, Sang Hyun Cho, Jeong Deuk Lee, Hei Sung Kim   +4 more
doaj   +1 more source

JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]

, 2016
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana, De Schepper, Sofie, Desmet, Eline, Lambert, Jo, Speeckaert, Reinhart, Van Gele, Mireille   +5 more
core   +14 more sources

A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs

Molecular & Cellular Oncology, 2021
While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder, Florian Perner, Florian H. Heidel   +2 more
doaj   +1 more source

Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2

Journal of Translational Medicine, 2022
Background JAK1 and JAK2 have been implicated in fibrosis and cancer as a fibroblast-related marker; however, their role in liver fibrosis has not been elucidated.
Zhenghui Song, Xinhui Liu, Wan Zhang, Yue Luo, Hua Xiao, Yun Liu, Guanqi Dai, Jian Hong, Aimin Li   +8 more
doaj   +1 more source

In silico method potential therapeutic use of Janus Kinase inhibitors as severe acute respiratory syndrome coronavirus 2 main protease inhibitors

Journal of the Scientific Society, 2023
Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge, Sushmita I Hiremath, Akshata S Menasinakai, Mahesh S Palled   +3 more
doaj   +1 more source

Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene Signature

Journal of Personalized Medicine, 2020
Pancreatic ductal adenocarcinoma (PDAC) is still one of the most aggressive and lethal cancer types due to the late diagnosis, high metastatic potential, and drug resistance. The development of novel therapeutic strategies is urgently needed.
Li-Wei Liu, Y. Hsieh, Pei-Ming Yang
semanticscholar   +1 more source

Overexpression of Janus kinase 2 protein in extramammary Paget’s disease [PDF]

Japanese Journal of Clinical Oncology, 2021
Abstract Extramammary Paget’s disease is a rare malignant tumor of the skin that occurs primarily in the genitocrural region. Although the prognosis of extramammary Paget’s disease with distant metastasis is poor, an effective therapy has not been established.
Saki, Otsuka-Maeda, Myangat Tselmeg, Mijiddorj, Ikko, Kajihara, Ryoko, Sakamoto, Saori, Yamada-Kanazawa, Hisashi, Kanemaru, Yuki, Nishimura, Soichiro, Sawamura, Katsunari, Makino, Jun, Aoi, Takamitsu, Makino, Shinichi, Masuguchi, Satoshi, Fukushima, Hironobu, Ihn   +13 more
openaire   +2 more sources